Articulating the Role of Antiplatelet Therapy in Patients With Acute Coronary Syndromes and Prior MI Challenges, Gray Areas, and Evolving Data
Articulating the Role of Antiplatelet Therapy in Patients With Acute Coronary Syndromes and Prior MI:
Challenges, Gray Areas, and Evolving Data
Release Date: June 30, 2020
Last Reviewed: June 20, 2020
Expiration Date: June 30, 2021
Time to Complete Activity: 2.0 Hours
*This activity expired for credit on June 30, 2021 and is no longer available for credit
Faculty
Deepak L. Bhatt, MD, MPH (Faculty Chair)
Professor of Medicine
Harvard Medical School
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Boston, MA
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Professor of Medicine
Director, Cardiovascular Research
Program Director, Interventional Cardiology Fellowship
University of Florida College of Medicine-Jacksonville
Division of Cardiology
Jacksonville, FL
Christopher Cannon, MD
Education Director, Cardiovascular Innovation
Preventive Cardiology Section, Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Christopher B. Granger, MD
Professor of Medicine
Director, Cardiac Intensive Care Unit
Duke University School of Medicine
Durham, NC
Michelle L. O’Donoghue, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Associate Physician, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
The Kent and Siri Rawson Director, Duke Program for Advanced Coronary Disease
Vice-Chair, Department of Medicine—Development and Innovation
Associate Director, Duke Heart Center
Senior Investigator, Duke Clinical Research Institute
Duke University Medical Center
Durham, NC
This activity is provided by Paradigm Medical Communications, LLC.
Target Audience
This activity has been designed to address the educational needs of clinical and interventional cardiologists, primary care physicians, nurse practitioners, and PAs. It may also benefit other clinicians who are involved in antiplatelet decision-making for patients who have acute coronary syndromes (ACS) and a history of myocardial infarction (MI).
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
- Select optimal antiplatelet treatment for heterogeneous patients with ACS and a history of MI based on current data
- Individualize the duration of dual antiplatelet therapy (DAPT) in patients with ACS and a history of MI based on the latest evidence and unique patient characteristics
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 2.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the preactivity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers:
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Deepak L. Bhatt, MD, MPH
Grant/Research Support: Abbott Laboratories; Afimmune Ltd; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cardax, Inc.; Chiesi USA; CLS Behring; Eisai Inc.; Eli Lilly and Company; Ethicon, Inc.; Ferring Pharmaceuticals Inc.; Forest Laboratories; Fractyl Laboratories Inc.; Indorsia Ltd; Ironwood Pharmaceuticals; Ischemix Inc.; Lexicon Pharmaceuticals, Inc.; Medtronic Inc.; Pfizer Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Regeneron Pharmaceuticals, Inc.; Roche Pharma; Sanofi US; Synaptic Pharmaceuticals Corp.; The Medicines Company
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI
Consulting Fees: Amgen Inc.; Aralez Pharmaceuticals Inc.; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Biosensors International Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Chiesi USA; Daiichi-Sankyo, Inc.; Eli Lilly and Company; Haemonetics Corporation; Janssen Pharmaceuticals; Merck & Co., Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Pfizer Inc.; Sanofi US; The Medicines Company
Grant/Research Support: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer Corporation; Biosensors International Ltd; CeloNova BioSciences, Inc.; CSL Behring; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Idorsia Ltd; Janssen Pharmaceuticals; Matsutani Chemical Industry Co., Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals; Osprey Medical, Inc.; RenalGuard Solutions, Inc.
Other: CeloNova BioSciences, Inc.; St. Jude’s Medical, Inc.
Christopher Cannon, MD
Consulting Fees: Aegerion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals; Amarin Corportion; Amgen Inc.; Applied Therapeutics, Inc.; Asecndia Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Corvidia Therapeutics; HLS Therapeutics, Inc.; Innovent Biologics, Inc.; Janssen Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Sanofi US
Grant/Research Support: Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi-Sankyo, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.
Christopher B. Granger, MD
Consulting Fees: AbbVie Inc.; Bayer Corporation; Boston Scientific Corporation; Espero Biopharma; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; CeleCor Therapeutics; Correvio Pharma Corp; Janssen Pharmaceuticals; Medscape; Medtronic Inc.; Merck & Co., Inc.; Novo Nordisk Inc.; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc.; Roche Diagnostics
Grant/Research Support: Akros Pharma Inc.; Apple; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Duke Clinical Research; GlaxoSmithKline plc; Janssen Pharmaceuticals; Medtronic Foundation; Novartis Pharmaceuticals; Pfizer Inc.
Michelle L. O’Donoghue, MD, MPH
Salary/Honoraria: Medscape Cardiology
Grant/Research Support: Amgen Inc.; AstraZeneca Pharmaceuticals LP; The Medicines Company
Consulting Fees: Amgen Inc.; AstraZeneca Pharmaceuticals LP; CRICO; Janssen Pharmaceuticals; Novartis Pharmaceuticals
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
No financial relationships to disclose.
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.